These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 23158844

  • 21. Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: a multicenter clinical experience.
    Ratnam D, Dev A, Nguyen T, Sundararajan V, Harley H, Cheng W, Lee A, Rusli F, Chen R, Bell S, Pianko S, Sievert W.
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1447-53. PubMed ID: 22168789
    [Abstract] [Full Text] [Related]

  • 22. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, Mach T, Boucher CA, Hansen BE, Zeuzem S, Janssen HL.
    Antivir Ther; 2012 Sep; 17(1):9-17. PubMed ID: 22267464
    [Abstract] [Full Text] [Related]

  • 23. [Dynamic changes of B7-H1 expression on mDCs and T cells in chronic hepatitis B patients treated with PEG-IFN alpha-2a].
    Li YG, Chen LE, Chen GF, Wang FS.
    Zhonghua Gan Zang Bing Za Zhi; 2008 Jun; 16(6):421-4. PubMed ID: 18578991
    [Abstract] [Full Text] [Related]

  • 24. [Changes and clinical significance of γδT cells in peripheral blood of patients with chronic hepatitis B during pegylated interferon α-2a treatment].
    Liu K, Shen YX, Ling N, Lei Y, Hu P, Ren H, Chen M.
    Zhonghua Gan Zang Bing Za Zhi; 2018 May 20; 26(5):365-370. PubMed ID: 29996205
    [Abstract] [Full Text] [Related]

  • 25. Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir.
    Stelma F, de Niet A, Tempelmans Plat-Sinnige MJ, Jansen L, Takkenberg RB, Reesink HW, Kootstra NA, van Leeuwen EM.
    J Infect Dis; 2015 Oct 01; 212(7):1042-51. PubMed ID: 25791117
    [Abstract] [Full Text] [Related]

  • 26. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
    Limothai U, Chuaypen N, Poovorawan K, Chotiyaputta W, Tanwandee T, Poovorawan Y, Tangkijvanich P.
    J Viral Hepat; 2019 Dec 01; 26(12):1481-1488. PubMed ID: 31446638
    [Abstract] [Full Text] [Related]

  • 27. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.
    Evans A, Riva A, Cooksley H, Phillips S, Puranik S, Nathwani A, Brett S, Chokshi S, Naoumov NV.
    Hepatology; 2008 Sep 01; 48(3):759-69. PubMed ID: 18697210
    [Abstract] [Full Text] [Related]

  • 28. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
    Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Janssen HL.
    Gastroenterology; 2009 Dec 01; 137(6):2002-9. PubMed ID: 19737568
    [Abstract] [Full Text] [Related]

  • 29. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
    Cai Q, Chen F, Shao X, Zhang X, Zhao Z, Gao Z.
    Antivir Ther; 2015 Dec 01; 20(2):217-24. PubMed ID: 25138110
    [Abstract] [Full Text] [Related]

  • 30. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?
    Kao JH.
    Liver Int; 2014 Feb 01; 34 Suppl 1():112-9. PubMed ID: 24373087
    [Abstract] [Full Text] [Related]

  • 31. [Changes in lymphocyte surface expression of CD8 and CD38 molecules in peripheral blood of inactive HBsAg carriers following pegylated interferon a-2a therapy].
    Yu HB, Ma LN, Liu YL, Hua W, He ZM, Lu JF, Chen XY.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Dec 01; 21(12):895-8. PubMed ID: 24636289
    [Abstract] [Full Text] [Related]

  • 32. TNF-α/IFN-γ profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection.
    Wang H, Luo H, Wan X, Fu X, Mao Q, Xiang X, Zhou Y, He W, Zhang J, Guo Y, Tan W, Deng G.
    J Hepatol; 2020 Jan 01; 72(1):45-56. PubMed ID: 31499130
    [Abstract] [Full Text] [Related]

  • 33. Interleukin-35 Suppresses Antiviral Immune Response in Chronic Hepatitis B Virus Infection.
    Shao X, Ma J, Jia S, Yang L, Wang W, Jin Z.
    Front Cell Infect Microbiol; 2017 Jan 01; 7():472. PubMed ID: 29181338
    [Abstract] [Full Text] [Related]

  • 34. Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B.
    Park JJ, Wong DK, Wahed AS, Lee WM, Feld JJ, Terrault N, Khalili M, Sterling RK, Kowdley KV, Bzowej N, Lau DT, Kim WR, Smith C, Carithers RL, Torrey KW, Keith JW, Levine DL, Traum D, Ho S, Valiga ME, Johnson GS, Doo E, Lok AS, Chang KM, Hepatitis B Research Network.
    Gastroenterology; 2016 Mar 01; 150(3):684-695.e5. PubMed ID: 26684441
    [Abstract] [Full Text] [Related]

  • 35. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M, Rabiega P, Ganne-Carrie N, Serfaty L, Marcellin P, Barthe Y, Thabut D, Guyader D, Hezode C, Picon M, Causse X, Leroy V, Bronowicki JP, Carrieri P, Riachi G, Rosa I, Attali P, Molina JM, Bacq Y, Tran A, Grangé JD, Zoulim F, Fontaine H, Alric L, Bertucci I, Bouvier-Alias M, Carrat F, ANRS HB06 PEGAN Study Group.
    Lancet Gastroenterol Hepatol; 2017 Mar 01; 2(3):177-188. PubMed ID: 28404133
    [Abstract] [Full Text] [Related]

  • 36. Pegylated Interferon α-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion.
    Bruder Costa J, Dufeu-Duchesne T, Leroy V, Bertucci I, Bouvier-Alias M, Pouget N, Brevot-Lutton O, Bourliere M, Zoulim F, Plumas J, Aspord C, ANRS HB06 PEGAN study group.
    PLoS One; 2016 Mar 01; 11(6):e0158297. PubMed ID: 27348813
    [Abstract] [Full Text] [Related]

  • 37. Ribavirin and IFN-alpha combination therapy induces CD4+ T-cell proliferation and Th1 cytokine secretion in patients with chronic hepatitis B.
    Ren FY, Jin H, Piao XX, Piao FS.
    World J Gastroenterol; 2007 Nov 07; 13(41):5440-5. PubMed ID: 17907286
    [Abstract] [Full Text] [Related]

  • 38. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W, Yuan H, Mao XR, Deng YD, Chen L.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar 07; 21(3):184-8. PubMed ID: 23967738
    [Abstract] [Full Text] [Related]

  • 39. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
    Luo X, Yu JX, Xie L, Ma WJ, Wang LH.
    Ann Hepatol; 2013 Mar 07; 16(6):888-892. PubMed ID: 29055925
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.